Document Detail


Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials.
MedLine Citation:
PMID:  19419254     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clevidipine is an arterial, selective, dihydropyridine calcium channel blocker with an ultrashort half-life. In this prospective, randomized, open-label, parallel-comparison trial series, the safety and efficacy of intravenous clevidipine with nitroglycerin, sodium nitroprusside and nicardipine in hypertensive patients during cardiac surgery were compared. No differences in the incidences of myocardial infarction, stroke or renal dysfunction were observed between treatment groups. Mortality was similar between the clevidipine-nitrogylcerine- and clevidipine-nicardipine-treated groups, whereas mortality appeared to be greater in the sodium nitroprusside group compared to clevidipine (p = 0.04 in a univariant analysis). Clevidipine was significantly more effective in blood pressure control compared with nitroglycerin (p = 0.0006) or sodium nitroprusside (p = 0.003) and was associated with fewer blood pressure excursions compared with nicardipine as a predetermined blood pressure range was narrowed.
Authors:
Solomon Aronson
Related Documents :
20083724 - Effects of potassium chloride and potassium bicarbonate on endothelial function, cardio...
7594124 - Blood pressure responses of white men with hypertension to two low-sodium metabolic die...
270994 - Use of a microprocessor in the control of malignant hypertension with sodium nitropruss...
6354534 - Differential blood pressure and metabolic effects of 9 alpha-fluorocortisol in man.
9203814 - Physiological outcomes of lung volume reduction surgery.
9097084 - Effects of medium-term antihypertensive therapy on haemostatic parameters in patients w...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  7     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-07     Completed Date:  2009-08-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  465-72     Citation Subset:  IM    
Affiliation:
Department of Anesthesiology, Duke University Medical Center, Duke South, Room 102 Baker House, Durham, NC 27710, USA. arons002@mc.duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Aged, 80 and over
Antihypertensive Agents / adverse effects,  therapeutic use
Calcium Channel Blockers / administration & dosage,  adverse effects*,  therapeutic use
Cardiac Surgical Procedures
Female
Humans
Hypertension / drug therapy*
Infusions, Intravenous
Intraoperative Complications / drug therapy
Male
Nicardipine / adverse effects,  therapeutic use
Nitroglycerin / adverse effects,  therapeutic use
Nitroprusside / adverse effects,  therapeutic use
Postoperative Complications / drug therapy
Prospective Studies
Pyridines / administration & dosage,  adverse effects*,  therapeutic use
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Pyridines; 0/clevidipine; 15078-28-1/Nitroprusside; 55-63-0/Nitroglycerin; 55985-32-5/Nicardipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Next Document:  Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.